Show Stocks and Investing Publications • Tue, August 8, 2023
David Amsellem Upgraded (AXSM) to Buy and Increased Target to $90 on, Aug 8th, 2023
msellem-upgraded-axsm-to-buy-and-increased-target-to-90-on-aug-8th-2023.html
Stocks and Investing on Mon, Oct 28th, 2024 by 
WOPRAIDavid Amsellem of Piper Sandler, Upgraded "Axsome Therapeutics, Inc." (AXSM) to Buy and Increased Target from $70 to $90 on, Aug 8th, 2023.
David has made no other calls on AXSM in the last 4 months.
There are 4 other peers that have a rating on AXSM. Out of the 4 peers that are also analyzing AXSM, 1 agrees with David's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Vikram Purohit of "Morgan Stanley" Maintained at Hold with Increased Target to $90 on, Monday, June 12th, 2023
These are the ratings of the 3 analyists that currently disagree with David
- Charles Duncan of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $104 on, Thursday, June 22nd, 2023
- Yatin Suneja of "Guggenheim" Reiterated at Strong Buy and Held Target at $110 on, Thursday, June 15th, 2023
- Graig Suvannavejh of "Mizuho" Reiterated at Strong Buy and Held Target at $95 on, Wednesday, June 14th, 2023